Certara in our Pivotal Point Check: FDA to Replace Animal Testing - AI as a Gamechanger in Drug Development!
Reading Time: 2 minutes
The FDA aims to replace animal testing with "human-relevant methods," including AI-based models. With the software from the drug developer, the behavior of medications in the human body can be simulated. Analysts from the investment firm Leerink Partners see a significantly positive boost for Certara. Shares of the drug developer Certara surged by over 20% on April 11, 2025, following the announcement from the U.S. FDA, under very high volume. The FDA announced that it intends to replace animal testing with "human-relevant methods,"...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
